Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (7)

Search Parameters:
Authors = Emily Kaplan ORCID = 0000-0001-7364-9925

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
13 pages, 1423 KiB  
Article
Advanced Diagnosis of Hypertrophic Cardiomyopathy with AI-ECG and Differences Based on Ethnicity and HCM Subtype
by Myra Lewontin, Emily Kaplan, Kenneth C. Bilchick, Anita Barber, Derek Bivona, Christopher M. Kramer, Anna Parrish, Karen McClean, Matthew Thomas, Allison Perry, Kaitlyn Amos and Michael Ayers
J. Clin. Med. 2025, 14(13), 4718; https://doi.org/10.3390/jcm14134718 - 3 Jul 2025
Viewed by 433
Abstract
Background/Objective: Hypertrophic cardiomyopathy (HCM) often presents later in the disease course, with frequent misdiagnoses and population-level underdiagnoses. Underserved patients may have even greater diagnostic delays. We aimed to test the hypothesis in a retrospective cohort that artificial intelligence analysis of ECGs (AI-ECG) could [...] Read more.
Background/Objective: Hypertrophic cardiomyopathy (HCM) often presents later in the disease course, with frequent misdiagnoses and population-level underdiagnoses. Underserved patients may have even greater diagnostic delays. We aimed to test the hypothesis in a retrospective cohort that artificial intelligence analysis of ECGs (AI-ECG) could have afforded the opportunity for earlier diagnosis of HCM in one health system. Methods: We collected all available ECGs from patients referred to an HCM Center of Excellence over 15 years, both before and after HCM diagnosis. We applied AI-ECG to each ECG in a blinded fashion to predict the probability of HCM. We calculated the time between each patient’s AI-ECG diagnosis and clinical diagnosis. We examined the sensitivity and specificity of AI-ECG for all patients, and by septal subtype and genetic test result. Results: 3499 ECGs were analyzed in 404 patients (age 56 ± 18 years, 52% female). AI-ECG correctly identified HCM in 155 patients with a sensitivity of 67%, specificity of 95%, positive predictive value of 94%, and a negative predictive value of 69%. The AUC was similar using mean probability from all ECGs for each patient (AUC 0.91 [0.88, 0.94]) or using probability from the first ECG (AUC 0.91 [0.87,0.93]). AI-ECG diagnosed 27 patients over 1 year before clinical diagnosis, and up to 16.3 years early. Black patients were more likely than White patients to have an AI-ECG diagnosis before a clinical diagnosis (p = 0.005). Conclusions: AI-ECG offers the potential for advanced HCM diagnosis. Differences in identification timing between subgroups highlight inequities in current care and show the potential of AI-ECG for the greatest benefit in underserved ethnic groups. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

14 pages, 2136 KiB  
Systematic Review
Jones Fracture in the National Football League
by Emily J. Luo, Albert T. Anastasio, Taylor Stauffer, Caitlin Grant, Christine J. Wu, Kevin A. Wu, Samantha Kaplan and Brian C. Lau
Sports 2024, 12(1), 7; https://doi.org/10.3390/sports12010007 - 25 Dec 2023
Cited by 1 | Viewed by 3936
Abstract
Background: Jones fracture, or proximal fifth metatarsal fracture, is a common injury in National Football League (NFL)-caliber athletes. Combine draft performance can greatly impact the long-term success of these athletes, and substantial emphasis has been placed on early return to play (RTP) and [...] Read more.
Background: Jones fracture, or proximal fifth metatarsal fracture, is a common injury in National Football League (NFL)-caliber athletes. Combine draft performance can greatly impact the long-term success of these athletes, and substantial emphasis has been placed on early return to play (RTP) and the minimization of post-operative complications after Jones fracture in these athletes. To date, no study has specifically described the treatment and outcomes of this injury specifically in NFL-caliber players, considering factors relevant to this unique population. Thus, the purpose of this review is to delve into Jones fracture in NFL-caliber athletes, evaluating the diagnostic, treatment, and RTP considerations. Methods: We searched Medline (PubMed), Embase (Elsevier), Scopus (Elsevier), and SPORTDiscus (EBSCOhost) for the concept of Jones fractures in the NFL. Using the PRISMA guidelines, a team of three reviewers conducted abstract screenings, full-text screenings, and the extraction of studies describing Jones fractures specifically in the NFL. Results: Of the 1911 studies identified, 6 primary retrospective studies met the inclusion and exclusion criteria. The heterogeneity of the outcome reporting precluded a meta-analysis; thus, a qualitative review of manuscripts describing Jones fracture was carried out. Classification, diagnosis, and treatment considerations, RTP statistics and outcomes, and complications were discussed. Amongst the primary studies, there were 285 Jones fractures, all athletes were able to RTP, and the average time to RTP ranged from 6 weeks to 27 weeks. For complications, with operative treatment, the refracture rate ranged from 4 to 12%, and incomplete healing ranged from 7 to 50%. RTP was 15 weeks for refractures. There were no patient-reported outcomes. Conclusions: The vast majority of Zone 2/3 Jones fractures are treated with IM screw fixation with or without adjunctive orthobiologics, such as bone marrow aspirate concentrate, in NFL-caliber athletes. The six major series investigating outcomes after the operative treatment of Jones fractures in NFL players reveal very positive findings overall with regard to RTP, reoperation, and career continuation. Full article
Show Figures

Figure 1

25 pages, 9038 KiB  
Review
The Story of Elaeagia Resin (Mopa-Mopa), So Far
by Richard Newman, Emily Kaplan and Maria Cecilia Álvarez-White
Heritage 2023, 6(5), 4320-4344; https://doi.org/10.3390/heritage6050229 - 12 May 2023
Cited by 8 | Viewed by 4640
Abstract
The unusual resin from some species of Elaeagia, a genus now found in certain parts of Central America and South America, was probably first utilized by native peoples in Colombia more than a thousand years ago. It became a crucial part of often [...] Read more.
The unusual resin from some species of Elaeagia, a genus now found in certain parts of Central America and South America, was probably first utilized by native peoples in Colombia more than a thousand years ago. It became a crucial part of often elaborately decorated objects made in the southwestern city of Pasto in the colonial period, and it has continued to be used there up to the present, in which it is at the core of a local craft tradition. The resin was also utilized for about 300 years by the Inka, mainly to decorate qeros (ceremonial drinking cups). The resin is often referred to as mopa-mopa and, specifically in Colombia, as barniz de Pasto. The botany, chemistry, properties, and analysis of Elaeagia resin are reviewed, along with a brief survey of the history of its use. Full article
(This article belongs to the Special Issue Lacquer in the Americas)
Show Figures

Figure 1

9 pages, 280 KiB  
Article
Back on the Road: Comparing Cognitive Assessments to Driving Simulators in Moderate to Severe Traumatic Brain Injuries
by Debra S. Ouellette, Stephanie Kaplan and Emily R. Rosario
Brain Sci. 2023, 13(1), 54; https://doi.org/10.3390/brainsci13010054 - 28 Dec 2022
Cited by 1 | Viewed by 2187
Abstract
Objective: To compare established clinical outcome assessments for predicting behind the wheel driving readiness and driving simulator results across age groups and in traumatic brain injury. Methods: Participants included adults who had a traumatic brain injury ranging in age from 31 to 57 [...] Read more.
Objective: To compare established clinical outcome assessments for predicting behind the wheel driving readiness and driving simulator results across age groups and in traumatic brain injury. Methods: Participants included adults who had a traumatic brain injury ranging in age from 31 to 57 years and a non-impaired adult population ranging in age from 18 to 80 years. Physical and cognitive outcomes measures were collected included range of motion and coordination, a “Rules of the Road Test” a “Sign Identification Test,” Trails A and B, and the clock drawing test. Visual measures included the Dynavision D2 system and motor-free visual perceptual test-3 (MVPT-3). Finally, the driving simulators (STIÒ version M300) metro drive assessment was used, which consisted of negotiating several obstacles in a metropolitan area including vehicles abruptly changing lanes, pedestrians crossing streets, and negotiating construction zones. Results: Our findings suggest that the standard paper-pencil cognitive assessments and sign identification test significantly differentiate TBI from a non-impaired population (Trails A, B and Clock drawing test p < 0.001). While the driving simulator did not show as many robust differences with age, the TBI population did have a significantly greater number of road collisions (F3, 78 = 3.5, p = 0.02). We also observed a significant correlation between the cognitive assessments and the simulator variables. Conclusions: Paper-pencil cognitive assessments and the sign identification test highlight greater differences than the STI Driving Simulator between non-impaired and TBI populations. However, the driving simulator may be useful in assessing cognitive ability and training for on the road driving. Full article
(This article belongs to the Special Issue Women in Brain Science: Achievements, Challenges and Perspectives)
13 pages, 688 KiB  
Article
Implementing the Federal Smoke-Free Public Housing Policy in New York City: Understanding Challenges and Opportunities for Improving Policy Impact
by Nan Jiang, Emily Gill, Lorna E. Thorpe, Erin S. Rogers, Cora de Leon, Elle Anastasiou, Sue A. Kaplan and Donna Shelley
Int. J. Environ. Res. Public Health 2021, 18(23), 12565; https://doi.org/10.3390/ijerph182312565 - 29 Nov 2021
Cited by 17 | Viewed by 3785
Abstract
In 2018, the U.S. Department of Housing and Urban Development required public housing authorities to implement a smoke-free housing (SFH) policy that included individual apartments. We analyzed the policy implementation process in the New York City Public Housing Authority (NYCHA). From June–November 2019, [...] Read more.
In 2018, the U.S. Department of Housing and Urban Development required public housing authorities to implement a smoke-free housing (SFH) policy that included individual apartments. We analyzed the policy implementation process in the New York City Public Housing Authority (NYCHA). From June–November 2019, we conducted 9 focus groups with 64 NYCHA residents (smokers and nonsmokers), 8 key informant interviews with NYCHA staff and resident association leaders, and repeated surveys with a cohort of 130 nonsmoking households pre- and 12-month post policy. One year post policy implementation, participants reported widespread smoking violations and multi-level factors impeding policy implementation. These included the shared belief among residents and staff that the policy overreached by “telling people what to do in their own apartments”. This hindered compliance and enforcement efforts. Inconsistent enforcement of illegal marijuana use, staff smoking violations, and a lack of accountability for other pressing housing issues created the perception that smokers were being unfairly targeted, as did the lack of smoking cessation resources. Resident support for the policy remained unchanged but satisfaction with enforcement declined (60.1% vs. 48.8%, p = 0.047). We identified multilevel contextual factors that are influencing SFH policy implementation. Findings can inform the design of strategies to optimize policy implementation. Full article
(This article belongs to the Section Health Behavior, Chronic Disease and Health Promotion)
Show Figures

Figure 1

15 pages, 1033 KiB  
Review
The Immunotherapy Landscape in Adrenocortical Cancer
by Guillaume J. Pegna, Nitin Roper, Rosandra N. Kaplan, Emily Bergsland, Katja Kiseljak-Vassiliades, Mouhammed Amir Habra, Yves Pommier and Jaydira Del Rivero
Cancers 2021, 13(11), 2660; https://doi.org/10.3390/cancers13112660 - 28 May 2021
Cited by 15 | Viewed by 5381
Abstract
Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal gland that is frequently associated with excess production of adrenal hormones. Although surgical resection may be curative in early-stage disease, few effective therapeutic options exist in the inoperable advanced or metastatic setting. Immunotherapies, [...] Read more.
Adrenocortical carcinoma (ACC) is a rare cancer of the adrenal gland that is frequently associated with excess production of adrenal hormones. Although surgical resection may be curative in early-stage disease, few effective therapeutic options exist in the inoperable advanced or metastatic setting. Immunotherapies, inclusive of a broad array of immune-activating and immune-modulating antineoplastic agents, have demonstrated clinical benefit in a wide range of solid and hematologic malignancies. Due to the broad activity across multiple cancer types, there is significant interest in testing these agents in rare tumors, including ACC. Multiple clinical trials evaluating immunotherapies for the treatment of ACC have been conducted, and many more are ongoing or planned. Immunotherapies that have been evaluated in clinical trials for ACC include the immune checkpoint inhibitors pembrolizumab, nivolumab, and avelumab. Other immunotherapies that have been evaluated include the monoclonal antibodies figitumumab and cixutumumab directed against the ACC-expressed insulin-like growth factor 1 (IGF-1) receptor, the recombinant cytotoxin interleukin-13-pseudomonas exotoxin A, and autologous tumor lysate dendritic cell vaccine. These agents have shown modest clinical activity, although nonzero in the case of the immune checkpoint inhibitors. Clinical trials are ongoing to evaluate whether this clinical activity may be augmented through combinations with other immune-acting agents or targeted therapies. Full article
(This article belongs to the Special Issue Malignant Adrenal Tumors – from Bench to Bedside)
Show Figures

Figure 1

14 pages, 1912 KiB  
Article
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
by Gilad Kaplan, Fred Lee, Masanori Onda, Emily Kolyvas, Gaurav Bhardwaj, David Baker and Ira Pastan
Toxins 2016, 8(8), 217; https://doi.org/10.3390/toxins8080217 - 25 Jul 2016
Cited by 27 | Viewed by 8239
Abstract
Recombinant immunotoxins (RITs) are fusions of an Fv-based targeting moiety and a toxin. Pseudomonas exotoxin A (PE) has been used to make several immunotoxins that have been evaluated in clinical trials. Immunogenicity of the bacterial toxin and off-target toxicity have limited the efficacy [...] Read more.
Recombinant immunotoxins (RITs) are fusions of an Fv-based targeting moiety and a toxin. Pseudomonas exotoxin A (PE) has been used to make several immunotoxins that have been evaluated in clinical trials. Immunogenicity of the bacterial toxin and off-target toxicity have limited the efficacy of these immunotoxins. To address these issues, we have previously made RITs in which the Fv is connected to domain III (PE24) by a furin cleavage site (FCS), thereby removing unneeded sequences of domain II. However, the PE24 containing RITs do not contain the naturally occurring disulfide bond around the furin cleavage sequence, because it was removed when domain II was deleted. This could potentially allow PE24 containing immunotoxins to be cleaved and inactivated before internalization by cell surface furin or other proteases in the blood stream or tumor microenvironment. Here, we describe five new RITs in which a disulfide bond is engineered to protect the FCS. The most active of these, SS1-Fab-DS3-PE24, shows a longer serum half-life than an RIT without the disulfide bond and has the same anti-tumor activity, despite being less cytotoxic in vitro. These results have significance for the production of de-immunized, low toxicity, PE24-based immunotoxins with a longer serum half-life. Full article
(This article belongs to the Collection Immunotoxins 2016)
Show Figures

Graphical abstract

Back to TopTop